Tempus AI, Inc. (TEM) stock declined over -2.07%, trading at $52.44 on NASDAQ, down from the previous close of $53.55. The stock opened at $54.51, fluctuating between $51.20 and $55.00 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 54.71 | 55.00 | 51.20 | 52.44 | 8.61M |
| Feb 04, 2026 | 55.50 | 55.51 | 49.88 | 53.55 | 9.57M |
| Feb 03, 2026 | 59.24 | 59.33 | 54.40 | 55.97 | 5.7M |
| Feb 02, 2026 | 59.43 | 59.99 | 57.51 | 58.55 | 5.24M |
| Jan 30, 2026 | 62.41 | 63.32 | 59.42 | 59.82 | 6.36M |
| Jan 29, 2026 | 64.04 | 64.22 | 62.65 | 63.51 | 4.77M |
| Jan 28, 2026 | 66.65 | 66.81 | 64.44 | 64.57 | 4.14M |
| Jan 27, 2026 | 67.88 | 68.57 | 66.22 | 66.81 | 3.68M |
| Jan 26, 2026 | 65.00 | 70.16 | 64.47 | 67.63 | 5.3M |
| Jan 23, 2026 | 68.81 | 68.95 | 64.84 | 65.32 | 3.89M |
| Jan 22, 2026 | 66.00 | 68.78 | 65.61 | 68.36 | 4M |
| Jan 21, 2026 | 66.63 | 67.30 | 61.82 | 65.32 | 7.16M |
| Jan 20, 2026 | 68.33 | 69.41 | 66.66 | 66.78 | 4.84M |
| Jan 16, 2026 | 69.50 | 71.88 | 68.57 | 70.33 | 4.84M |
| Jan 15, 2026 | 69.70 | 73.26 | 68.56 | 68.92 | 6.85M |
| Jan 14, 2026 | 66.84 | 69.34 | 66.15 | 69.28 | 4.2M |
| Jan 13, 2026 | 69.73 | 70.56 | 66.08 | 67.15 | 6.8M |
| Jan 12, 2026 | 75.34 | 76.33 | 68.32 | 69.26 | 15.89M |
| Jan 09, 2026 | 69.81 | 69.88 | 66.17 | 66.27 | 3.12M |
| Jan 08, 2026 | 69.06 | 69.64 | 67.33 | 68.36 | 3.32M |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Employees | 2400 |
| Beta | 5.23 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 7.614% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Healthcare Information Services |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep